Published in Lung Cancer on March 01, 1994
Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance. Antimicrob Agents Chemother (1998) 0.76
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (1984) 6.23
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials (2000) 6.17
Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood (1980) 6.17
Music and spatial task performance. Nature (1993) 5.31
Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res (1985) 5.02
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg (1997) 4.47
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (1985) 4.47
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol (2000) 4.10
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A (1990) 4.06
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell (1998) 3.86
The role of increasing detection in the rising incidence of prostate cancer. JAMA (1995) 3.79
Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol (1991) 3.59
Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science (1994) 3.57
Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. Proc Natl Acad Sci U S A (1980) 3.39
Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2007) 3.24
NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res (1998) 3.20
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer (1998) 3.12
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
Molecular genetics of small cell lung carcinoma. Semin Oncol (2001) 3.02
Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene (1990) 2.97
A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst (2000) 2.95
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst (1997) 2.83
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
NCI series of cell lines: an historical perspective. J Cell Biochem Suppl (1996) 2.75
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res (1998) 2.72
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature (1987) 2.59
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst (1997) 2.52
Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res (2001) 2.50
Trends in biomarker research for cancer detection. Lancet Oncol (2001) 2.46
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst (2000) 2.45
Synchronization between prefrontal and posterior association cortex during human working memory. Proc Natl Acad Sci U S A (1998) 2.44
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol (2007) 2.43
Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest (1998) 2.39
Chemotherapy for non-small cell lung cancer. BMJ (1995) 2.39
Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs. Arch Intern Med (1993) 2.36
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest (1997) 2.30
Dendritic bundles: survey of anatomical experiments and physiological theories. Brain Res (1979) 2.30
Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene (2007) 2.27
Production of "authentic" poliovirus RNA-dependent RNA polymerase (3D(pol)) by ubiquitin-protease-mediated cleavage in Escherichia coli. Protein Expr Purif (1999) 2.24
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res (2000) 2.24
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer (2008) 2.21
Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A (1998) 2.20
Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst (1995) 2.18
Conservation of autosomal gene synteny groups in mouse and man. Nature (1978) 2.18
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene (2006) 2.14
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet (2001) 2.13
Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A (1989) 2.13
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res (1986) 2.12
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res (1985) 2.12
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene (1998) 2.10
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res (1992) 2.09
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res (2000) 2.07
An antitermination protein engages the elongating transcription apparatus at a promoter-proximal recognition site. Cell (1987) 2.07
High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science (1981) 2.07